Project Grant R21AG091124
- This federal Project Grant award of $3,221,450.00 from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to define how neuronal hyperexcitability in the retrosplenial cortex (RSC) contributes to the development of Alzheimer's disease (AD)-related behavioral deficits in mouse models. The research aims to determine the effect of inhibiting RSC layer 5 cells on spatial memory and navigation, as well as when hyperexcitability emerges in these cells across different AD...
- This $1,221,276 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the "In Vivo Single-Cell Analysis of Alzheimer's Disease-Associated Regulatory Elements" research project at the University of North Carolina at Chapel Hill. The project aims to develop a novel genomic platform called Single-Cell Massively Parallel Reporter Assays (SCMPRA) to investigate how Alzheimer's disease-associated regulatory elements orchestrate gene expression...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $427,625 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop and validate a computational framework for identifying excitation-inhibition imbalances in Alzheimer's disease (AD) using multi-modal neuroimaging data. The goal is to create an innovative technique that can noninvasively detect circuit-level disruptions in brain networks associated with AD pathology, which...
- This federal Project Grant award of $839,933 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to investigate the role of N6-methyladenosine (m6A) RNA modifications in microglial dysfunction and Alzheimer's disease (AD) pathogenesis. The project aims to systematically map m6A modification landscapes in microglia isolated from human brain tissue and human induced pluripotent stem cell-derived microglial models. The researchers will also use CRISPR-based...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $167,940 project grant to The Children's Hospital Corporation (Boston Children's Hospital) to elucidate the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease. The project, awarded on August 15, 2025, aims to (1) determine if the MEF2 transcription factors mediate survival of specific neuronal subtypes vulnerable to Alzheimer's pathology, (2) assess whether...
- This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
- This federal Project Grant award of $2,316,710 from the National Institute on Aging (CFDA 93.866 Aging Research) aims to develop magnetogenetic techniques for manipulating the activity of specific brain cell types implicated in the onset and progression of Alzheimer's disease (AD). The research will focus on using a magnetogenetic tool called FERIC (Ferritin Iron Redistribution to Ion Channels) in combination with enhancer AAV vectors to non-invasively control the activity of AD-vulnerable...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $412,500 Project Grant to the University of South Florida to investigate changes in the brain extracellular matrix during normal aging and in Alzheimer's disease. The 2-year grant, which runs from Jun 1, 2025 to May 31, 2027, aims to establish region-specific extracellular matrix composition in mouse brains, elucidate changes during normal aging, and characterize temporal and spatial...
- The National Institute on Aging (NIA) awarded a $1,459,072 project grant to the J. David Gladstone Institutes under the Aging Research Federal Grant Program (CFDA 93.866) to monitor and manipulate inhibitory interneuron cell populations in mouse models of Alzheimer's disease. The 2-year project aims to use dual cell-type-specific enhancer-associated adeno-associated viruses (enhancer-AAVs) to independently monitor and control parvalbumin (PVALB) and somatostatin (SST) inhibitory interneurons...
The federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $426,674 to the University of North Carolina at Chapel Hill to investigate the "Implications of Long-Range Mossy Cell Signaling and Connectivity in Alzheimer's Disease (AD)". The 2-year project, starting on September 1, 2025, aims to identify changes in the activity of glutamatergic mossy cells in the dentate gyrus of the hippocampus and their impact on broader hippocampal circuitry under pathological conditions of AD. The research seeks to elucidate how mossy cell dysfunction may contribute to the cognitive and affective impairments associated with AD, with the goal of informing the development of novel therapeutic interventions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $426.7k | 8/28/25 |